A recent Kabel et al. [50] publication reports that topiramate might be an effective adjuvant line of treatment of colon cancer in the future due to its properties of declining tissue VEGF, decreasing serum CEA and positively impacting body weight gain. The gene discussed is VEGFA; the disease is malignant colon neoplasm.